Matrix's Lansoprazole approved

Friday 13th November 2009

Mylan's Indian subsidiary Matrix Laboratories has received US Food and Drug Administration (FDA) approval for its Lansoprazole delayed-release capsules.

They are a generic version of Tap Pharmaceuticals' Prevacid proton pump inhibitor capsules, which had US sales of $3 billion for the 12 months ending June 30.

Mylan reportedly has 125 abbreviated new drug applications (ANDAs) pending approval, which represent $84 billion in annual brand sales. Of these, 37 are potential first-to-file applications worth $19 billion a year.

Mylan is a world-ranking generic pharmaceutical company selling into 140 countries and territories. It has one of the industry's broadest product portfolios and is the third-largest drug manufacturer, including respiratory and allergy treatments.

Copyright Press Association 2009

Lansoprazole

Feedback

Have YOUR say.

Name:
Email:
Location:

We welcome all feedback. However, we cannot publish anonymous comments, so please supply your name and location. Your details will not be displayed if you so request. To protect privacy we never publish email addresses.